The adalimumab, infliximab and etanercept biosimilars market size has grown exponentially in recent years. It will grow from $3.67 billion in 2023 to $4.41 billion in 2024 at a compound annual growth rate (CAGR) of 20.3%. The growth observed in the historical period can be attributed to several factors, including an upsurge in healthcare expenditure, regulatory changes, government initiatives, and the escalation of healthcare costs.
The adalimumab, infliximab and etanercept biosimilars market size is expected to see rapid growth in the next few years. It will grow to $6.79 billion in 2028 at a compound annual growth rate (CAGR) of 11.4%. The anticipated growth in the forecast period can be attributed to an increase in healthcare expenditure, the aging population, and an enhanced accessibility to healthcare, all of which are poised to drive market growth. Significant trends expected in the forecast period involve a concentrated effort on launching new products, a strategic emphasis on mergers and acquisitions, a proactive approach to establishing strategic partnerships, and a heightened focus on increasing investments.
The entrance of biosimilars into the market for adalimumab, infliximab, and etanercept is facilitated by the patent expiration of branded drugs. Notably, the FDA approved Hospira's Inflectra post the patent expiry of the branded drug Remicade, enabling treatment for various autoimmune diseases such as rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis in the United States. Similarly, in the EU, Amgen's Enbrel patent expiration led to the approval of Benepali, a biosimilar of Enbrel, by the European Commission. Following the expiry of Humira's patent, multiple biosimilars have become available in the market, including the recent approval (July 2020) of Hulio, the sixth biosimilar of Humira by the FDA. Consequently, the patent expiry of branded biologic drugs such as Humira, Enbrel, and Remicade is expected to propel demand in the adalimumab, infliximab, and etanercept biosimilars market.
The escalating prevalence of autoimmune diseases is anticipated to drive growth in the market for adalimumab, infliximab, and etanercept biosimilars. Autoimmune diseases arise from immune system dysfunction, leading immune cells to attack the body's healthy cells. Adalimumab, infliximab, and etanercept, as biological drugs with tumor necrosis factor (TNF) alpha inhibitors, are employed in treating various autoimmune diseases. According to Johns Hopkins University in 2023, approximately 10 million individuals in the US, constituting 3% of the population, are affected by diverse autoimmune illnesses. Consequently, the surge in autoimmune diseases' prevalence significantly contributes to driving the growth of the adalimumab, infliximab, and etanercept biosimilars market.
The escalating costs associated with brand-name versions of biosimilar drugs have paved the way for the adoption of lower-cost biosimilar alternatives upon the expiry of their patents. Notably, the expenses linked to branded biological drugs have nearly doubled in recent years, exemplified by the cost surge of Humira, a top-selling drug, which exceeded $72,000 in 2020. The transition to cost-effective biosimilar drugs is primarily driven by the absence of clinically significant differences in safety and efficacy between biosimilars and the original biologics. A striking example is the Danish healthcare system's extensive shift to adalimumab biosimilars following the expiration of the patent for the original adalimumab product, Humira. This transition resulted in an impressive 82% reduction in medication costs.
Major companies in the adalimumab, infliximab, and etanercept biosimilars market are prioritizing the development of innovative products, such as citrate-free adalimumab, to offer enhanced services to consumers. Citrate-free adalimumab represents a formulation of the biological medication adalimumab devoid of citrate. For instance, in December 2022, Fresenius Kabi, a German-based manufacturer specializing in medicines and technologies for infusion, transfusion, and clinical nutrition, announced FDA approval for the biosimilar Idacio (adalimumab). This biosimilar is sanctioned for use in managing chronic autoimmune disorders across all permissible uses of the reference product. It has been meticulously crafted employing advanced analytical methodologies, intended for the treatment of various chronic conditions.
In February 2022, the Indian biopharmaceutical company Biocon Limited successfully acquired the biosimilar assets of Viatris, Inc., a U.S.-based biopharmaceutical and healthcare company, for a total of $3.34 billion. This strategic acquisition positions Biocon as a unique and vertically integrated global leader in biosimilars, providing an impetus for the expedited commercialization of its existing and future biosimilar portfolio on a global scale. The move is set to significantly enhance Biocon's product reach across international markets. Viatris, Inc. is recognized for its expertise in the development and specialization of biological and therapeutic agents.
Major companies operating in the adalimumab, infliximab and etanercept biosimilars market report are Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., Bio-Thera Solutions, Ltd., Innovent Biologics (Suzhou) Co. Ltd., Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd., Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd., Mabwell Bioscience Co. Ltd., LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd., mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad, Roche, Bristol-Myers Squibb, Celon Pharma, SynBio, Celgene Corporation, AstraZeneca, Merck & Co, Gilead Sciences, Regeneron Pharmaceuticals, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Ache, Eurofarma, Sanofi, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Mylan, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty) Ltd.
North America was the largest region in the adalimumab, infliximab and etanercept biosimilars market in 2023. The regions covered in the adalimumab, infliximab and etanercept biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adalimumab, infliximab and etanercept biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
These medications include various products such as adalimumab, infliximab, cipleumab, and etanercept. Adalimumab, classified as a biological drug, operates on the immune system to mitigate inflammation. Its diverse applications encompass treating conditions such as Crohn’s disease, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, plaque psoriasis, and others. These products are made available through different distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.
The adalimumab, infliximab, and etanercept biosimilars market research report is one of a series of new reports that provides adalimumab, infliximab, and etanercept biosimilars market statistics, including adalimumab, infliximab, and etanercept biosimilars industry global market size, regional shares, competitors with adalimumab, infliximab, and etanercept biosimilars market. This adalimumab, infliximab, and etanercept biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The adalimumab, infliximab, and etanercept biosimilars market consists of sales of Amgevita, Hyrimoz, and Idacio. Values in this market are ""factory gate values,"" that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The adalimumab, infliximab and etanercept biosimilars market size is expected to see rapid growth in the next few years. It will grow to $6.79 billion in 2028 at a compound annual growth rate (CAGR) of 11.4%. The anticipated growth in the forecast period can be attributed to an increase in healthcare expenditure, the aging population, and an enhanced accessibility to healthcare, all of which are poised to drive market growth. Significant trends expected in the forecast period involve a concentrated effort on launching new products, a strategic emphasis on mergers and acquisitions, a proactive approach to establishing strategic partnerships, and a heightened focus on increasing investments.
The entrance of biosimilars into the market for adalimumab, infliximab, and etanercept is facilitated by the patent expiration of branded drugs. Notably, the FDA approved Hospira's Inflectra post the patent expiry of the branded drug Remicade, enabling treatment for various autoimmune diseases such as rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis in the United States. Similarly, in the EU, Amgen's Enbrel patent expiration led to the approval of Benepali, a biosimilar of Enbrel, by the European Commission. Following the expiry of Humira's patent, multiple biosimilars have become available in the market, including the recent approval (July 2020) of Hulio, the sixth biosimilar of Humira by the FDA. Consequently, the patent expiry of branded biologic drugs such as Humira, Enbrel, and Remicade is expected to propel demand in the adalimumab, infliximab, and etanercept biosimilars market.
The escalating prevalence of autoimmune diseases is anticipated to drive growth in the market for adalimumab, infliximab, and etanercept biosimilars. Autoimmune diseases arise from immune system dysfunction, leading immune cells to attack the body's healthy cells. Adalimumab, infliximab, and etanercept, as biological drugs with tumor necrosis factor (TNF) alpha inhibitors, are employed in treating various autoimmune diseases. According to Johns Hopkins University in 2023, approximately 10 million individuals in the US, constituting 3% of the population, are affected by diverse autoimmune illnesses. Consequently, the surge in autoimmune diseases' prevalence significantly contributes to driving the growth of the adalimumab, infliximab, and etanercept biosimilars market.
The escalating costs associated with brand-name versions of biosimilar drugs have paved the way for the adoption of lower-cost biosimilar alternatives upon the expiry of their patents. Notably, the expenses linked to branded biological drugs have nearly doubled in recent years, exemplified by the cost surge of Humira, a top-selling drug, which exceeded $72,000 in 2020. The transition to cost-effective biosimilar drugs is primarily driven by the absence of clinically significant differences in safety and efficacy between biosimilars and the original biologics. A striking example is the Danish healthcare system's extensive shift to adalimumab biosimilars following the expiration of the patent for the original adalimumab product, Humira. This transition resulted in an impressive 82% reduction in medication costs.
Major companies in the adalimumab, infliximab, and etanercept biosimilars market are prioritizing the development of innovative products, such as citrate-free adalimumab, to offer enhanced services to consumers. Citrate-free adalimumab represents a formulation of the biological medication adalimumab devoid of citrate. For instance, in December 2022, Fresenius Kabi, a German-based manufacturer specializing in medicines and technologies for infusion, transfusion, and clinical nutrition, announced FDA approval for the biosimilar Idacio (adalimumab). This biosimilar is sanctioned for use in managing chronic autoimmune disorders across all permissible uses of the reference product. It has been meticulously crafted employing advanced analytical methodologies, intended for the treatment of various chronic conditions.
In February 2022, the Indian biopharmaceutical company Biocon Limited successfully acquired the biosimilar assets of Viatris, Inc., a U.S.-based biopharmaceutical and healthcare company, for a total of $3.34 billion. This strategic acquisition positions Biocon as a unique and vertically integrated global leader in biosimilars, providing an impetus for the expedited commercialization of its existing and future biosimilar portfolio on a global scale. The move is set to significantly enhance Biocon's product reach across international markets. Viatris, Inc. is recognized for its expertise in the development and specialization of biological and therapeutic agents.
Major companies operating in the adalimumab, infliximab and etanercept biosimilars market report are Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., Bio-Thera Solutions, Ltd., Innovent Biologics (Suzhou) Co. Ltd., Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd., Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd., Mabwell Bioscience Co. Ltd., LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd., mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad, Roche, Bristol-Myers Squibb, Celon Pharma, SynBio, Celgene Corporation, AstraZeneca, Merck & Co, Gilead Sciences, Regeneron Pharmaceuticals, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Ache, Eurofarma, Sanofi, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Mylan, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty) Ltd.
North America was the largest region in the adalimumab, infliximab and etanercept biosimilars market in 2023. The regions covered in the adalimumab, infliximab and etanercept biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adalimumab, infliximab and etanercept biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
These medications include various products such as adalimumab, infliximab, cipleumab, and etanercept. Adalimumab, classified as a biological drug, operates on the immune system to mitigate inflammation. Its diverse applications encompass treating conditions such as Crohn’s disease, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, plaque psoriasis, and others. These products are made available through different distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.
The adalimumab, infliximab, and etanercept biosimilars market research report is one of a series of new reports that provides adalimumab, infliximab, and etanercept biosimilars market statistics, including adalimumab, infliximab, and etanercept biosimilars industry global market size, regional shares, competitors with adalimumab, infliximab, and etanercept biosimilars market. This adalimumab, infliximab, and etanercept biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The adalimumab, infliximab, and etanercept biosimilars market consists of sales of Amgevita, Hyrimoz, and Idacio. Values in this market are ""factory gate values,"" that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Adalimumab, Infliximab and Etanercept Biosimilars Market Characteristics3. Adalimumab, Infliximab and Etanercept Biosimilars Market Trends and Strategies32. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Competitive Benchmarking33. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Competitive Dashboard34. Key Mergers and Acquisitions in the Adalimumab, Infliximab and Etanercept Biosimilars Market
4. Adalimumab, Infliximab and Etanercept Biosimilars Market - Macro Economic Scenario
5. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Size and Growth
6. Adalimumab, Infliximab and Etanercept Biosimilars Market Segmentation
7. Adalimumab, Infliximab and Etanercept Biosimilars Market Regional and Country Analysis
8. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market
9. China Adalimumab, Infliximab and Etanercept Biosimilars Market
10. India Adalimumab, Infliximab and Etanercept Biosimilars Market
11. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market
12. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market
13. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market
14. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market
15. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market
16. UK Adalimumab, Infliximab and Etanercept Biosimilars Market
17. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market
18. France Adalimumab, Infliximab and Etanercept Biosimilars Market
19. Italy Adalimumab, Infliximab and Etanercept Biosimilars Market
20. Spain Adalimumab, Infliximab and Etanercept Biosimilars Market
21. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market
22. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market
23. North America Adalimumab, Infliximab and Etanercept Biosimilars Market
24. USA Adalimumab, Infliximab and Etanercept Biosimilars Market
25. Canada Adalimumab, Infliximab and Etanercept Biosimilars Market
26. South America Adalimumab, Infliximab and Etanercept Biosimilars Market
27. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market
28. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market
29. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market
30. Adalimumab, Infliximab and Etanercept Biosimilars Market Competitive Landscape and Company Profiles
31. Adalimumab, Infliximab and Etanercept Biosimilars Market Other Major and Innovative Companies
35. Adalimumab, Infliximab and Etanercept Biosimilars Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on adalimumab, infliximab and etanercept biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for adalimumab, infliximab and etanercept biosimilars? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Product: Adalimumab Biosimilars; Infliximab Biosimilars; Cipleumab
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By Application: Crohn’s Disease; Psoriatic Arthritis; Rheumatoid Arthritis; Ulcerative Colitis; Ankylosing Spondylitis; Plaque Psoriasis; Other Applications
Key Companies Mentioned: Biogen; Novartis (Sandoz); Pfizer; Amgen; Celltrion
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Biogen
- Novartis (Sandoz)
- Pfizer
- Amgen
- Celltrion
- Samsung Bioepis (Samsung Biologics)
- Hetero Drugs Limited
- Fresenius Kabi AG
- Boehringer Ingelheim
- Biocon
- Zydus Lifesciences Limited
- Reliance Life Sciences
- Torrent Pharmaceuticals Ltd
- Sun Pharmaceutical Industries Ltd
- Cipla Limited
- Zhejiang Hisun Pharmaceutical Co. Ltd
- Bio-Thera Solutions, Ltd
- Innovent Biologics (Suzhou) Co. Ltd
- Janssen Biologics BV
- Shanghai CP Guojian Pharmaceutical Co. Ltd
- Sansheng Guojian
- Shanghai Junshi Biosciences Co. Ltd
- Mabwell Bioscience Co. Ltd
- LG Chem
- Nippon Kayaku
- Mochida Pharmaceutical Co. Ltd
- mAbxience
- Allergan
- Microgen
- Geropharm
- Valenta
- NovaMedica Veropharm
- Biocad
- Roche
- Bristol-Myers Squibb
- Celon Pharma
- SynBio
- Celgene Corporation
- AstraZeneca
- Merck & Co
- Gilead Sciences
- Regeneron Pharmaceuticals
- Rani Therapeutics
- Eli Lilly and Company
- Emisphere Technologies Inc
- Enteris BioPharma
- Allena Pharmaceuticals
- Abbvie
- Johnson & Johnson
- Ache
- Eurofarma
- Sanofi
- Teva Pharmaceuticals
- Oramed Pharmaceuticals
- Entera Bio
- Julphar
- Hikma Pharmaceuticals
- Mylan
- BIOPHARMA-MEA
- NeoTX
- AID Genomics Limited
- Altis Biologics
- Cipla Medpro South Africa
- Next Biosciences
- Viome
- Inqaba Biotechnical Industries (Pty) Ltd
Methodology
LOADING...